About Quoin Pharmaceuticals DRC
Quoin Pharmaceuticals (NASDAQ:QNRX) focuses primarily on developing innovative treatments for rare and serious diseases. This company, with its dedication to addressing unmet medical needs, is active in various stages of research and development. Quoin Pharmaceuticals' portfolio includes projects aimed at tackling conditions that currently lack sufficient treatment options, highlighting its commitment to improving patient outcomes. Their objective is not just to advance healthcare but to revolutionize it by bringing forward novel therapies that can significantly impact people's lives. Quoin Pharmaceuticals trades exclusively on the NASDAQ stock exchange under the ticker symbol QNRX, reflecting its position within the global financial market and highlighting its accessibility to investors interested in contributing to healthcare advancements.
Snapshot
Operations
Produtos e/ou serviços de Quoin Pharmaceuticals DRC
- Development of innovative treatments for rare and orphan diseases, prioritizing conditions with significant unmet medical needs.
- Research and production of dermatological solutions to address severe skin diseases and conditions.
- Creation of advanced pain management drugs aimed at chronic and acute conditions, enhancing patient quality of life.
- Expansion into pediatric medicines, focusing on developing safe and effective treatments for children with rare diseases.
- Partnership with other pharmaceutical companies for the co-development and licensing of groundbreaking medical therapies.
- Investment in biotechnology advancements to support the creation of novel drug delivery systems and improve therapeutic outcomes.
equipe executiva do Quoin Pharmaceuticals DRC
- Dr. Michael Myers Ph.D.Co-Founder, CEO & Chairman
- Ms. Denise CarterCo-Founder, COO & Director
- Ms. Sally LawlorChief Financial Officer